TCA cycle, a critical metabolic pathway underlying tumor cell metabolism for energy production to the cell, is reported to be a novel immune checkpoint blockade as inhibiting it could improve the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis [65]. This evidence concerns the gene CD274 and neoplasm.